Linked Data API

Show Search Form

Search Results

758509
star this property registered interest false more like this
star this property date less than 2017-08-29more like thismore than 2017-08-29
star this property answering body
Department for Exiting the European Union more like this
star this property answering dept id 203 more like this
star this property answering dept short name Exiting the European Union more like this
unstar this property answering dept sort name Exiting the European Union more like this
star this property hansard heading National Security more like this
star this property house id 1 more like this
star this property legislature
25259
unstar this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Exiting the European Union, what discussions he has had with Cabinet colleagues on ensuring future cooperation with the EU on security policy after the UK has left the EU. more like this
star this property tabling member constituency Thornbury and Yate more like this
star this property tabling member printed
Luke Hall remove filter
star this property uin 900656 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2017-09-07more like thismore than 2017-09-07
star this property answer text <p>DExEU ministers regularly discuss exit issues with Cabinet and Ministerial colleagues. This includes security. <br><br>The Prime Minister has been clear that we will continue to work closely with our European partners to tackle a range of security issues.<br><br>The safety of the British public is a top priority. That security is enhanced through cooperating with Europe. The UK has always been, and will continue to be, a major global player in the fight against threats to security. <br><br>With the threat constantly evolving, our response must be to work more closely with our partners, including the EU and its Member States, sharing information and supporting each other in combating the threats posed by those who wish us harm.</p> more like this
star this property answering member constituency Worcester more like this
unstar this property answering member printed Mr Robin Walker more like this
star this property question first answered
less than 2017-09-07T15:40:54.983Zmore like thismore than 2017-09-07T15:40:54.983Z
star this property answering member
4091
star this property label Biography information for Mr Robin Walker more like this
star this property tabling member
4450
unstar this property label Biography information for Luke Hall more like this
860725
star this property registered interest false more like this
star this property date less than 2018-03-12more like thismore than 2018-03-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
unstar this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi more like this
star this property house id 1 more like this
star this property legislature
25259
unstar this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what progress has been made on negotiations between NHS England and Vertex Pharmaceuticals on access to the drug Orkambi for people with cystic fibrosis. more like this
star this property tabling member constituency Thornbury and Yate more like this
star this property tabling member printed
Luke Hall remove filter
star this property uin 132082 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-03-20more like thismore than 2018-03-20
star this property answer text <p>NHS England is currently in discussion with Vertex about its range of drugs for treating cystic fibrosis, including the drug Orkambi. NHS England will continue to support discussions with pharmaceutical companies that aim to provide clinically effective medicines to patients at a level that is cost-effective, in line with standard National Institute for Health and Care Excellence practice for assessing new drugs before they are introduced into the National Health Service.</p> more like this
star this property answering member constituency Winchester more like this
unstar this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-03-20T16:40:41.203Zmore like thismore than 2018-03-20T16:40:41.203Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4450
unstar this property label Biography information for Luke Hall more like this
942538
star this property registered interest false more like this
star this property date less than 2018-07-16more like thismore than 2018-07-16
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
unstar this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi more like this
star this property house id 1 more like this
star this property legislature
25259
unstar this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care what plans he has to ensure his Department continues to engage and meet with NHS England and Vertex to discuss access to Orkambi. more like this
star this property tabling member constituency Thornbury and Yate more like this
star this property tabling member printed
Luke Hall remove filter
star this property uin 164468 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-07-20more like thismore than 2018-07-20
star this property answer text <p>NHS England has been in intensive discussions with Vertex to encourage it to price Orkambi at a level that would allow NHS England to fund its use without adversely impacting other patients. I and the Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy) have been keeping an extremely close eye on these discussions and wrote to Vertex in April, urging it to commit to pricing that is responsible and proportionate. I also re-iterated this message in the adjournment debate on 17 July, Official report, columns 383-4.</p> more like this
star this property answering member constituency Winchester more like this
unstar this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-07-20T10:09:26.39Zmore like thismore than 2018-07-20T10:09:26.39Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4450
unstar this property label Biography information for Luke Hall more like this
942539
star this property registered interest false more like this
star this property date less than 2018-07-16more like thismore than 2018-07-16
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
unstar this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi more like this
star this property house id 1 more like this
star this property legislature
25259
unstar this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether ensuring access to Orkambi for people with cystic fibrosis is a priority for his Department. more like this
star this property tabling member constituency Thornbury and Yate more like this
star this property tabling member printed
Luke Hall remove filter
star this property uin 164469 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-07-20more like thismore than 2018-07-20
star this property answer text <p>It is a key commitment of this Government to ensure that people with comparatively rarer conditions, like cystic fibrosis, get the same quality, safety and efficacy in medicines as those who have more common conditions.</p><p> </p><p>However, it is also necessary that Vertex prices Orkambi fairly and responsibly. That is why we must go through the right process with Vertex and NHS England, not the Government, working together to secure the best outcome for patients. NHS England has been in intensive discussions with Vertex to encourage it to price Orkambi at a level that would allow NHS England to fund its use without adversely impacting other patients. I and the Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy) have been keeping an extremely close eye on these discussions and wrote to Vertex in April, urging it to commit to pricing that is responsible and proportionate. I also re-iterated this message in the adjournment debate on 17 July, Official report, columns 383-4.</p>
star this property answering member constituency Winchester more like this
unstar this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-07-20T10:10:54.173Zmore like thismore than 2018-07-20T10:10:54.173Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4450
unstar this property label Biography information for Luke Hall more like this
942540
star this property registered interest false more like this
star this property date less than 2018-07-16more like thismore than 2018-07-16
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
unstar this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi more like this
star this property house id 1 more like this
star this property legislature
25259
unstar this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether a date has been set for the next meeting between NHS England and Vertex to discuss access to the drug Orkambi. more like this
star this property tabling member constituency Thornbury and Yate more like this
star this property tabling member printed
Luke Hall remove filter
star this property uin 164470 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-07-20more like thismore than 2018-07-20
star this property answer text <p>We are informed by NHS England that at the last meeting on 4 July, it was agreed that both parties would take time to reflect before a further meeting was arranged. NHS England has subsequently made a substantially increased proposal to Vertex and has offered to meet to discuss and clarify any aspects as required by the company.</p> more like this
star this property answering member constituency Winchester more like this
unstar this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-07-20T09:48:08.57Zmore like thismore than 2018-07-20T09:48:08.57Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4450
unstar this property label Biography information for Luke Hall more like this
942541
star this property registered interest false more like this
star this property date less than 2018-07-16more like thismore than 2018-07-16
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
unstar this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi more like this
star this property house id 1 more like this
star this property legislature
25259
unstar this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what his Department's policy is on Vertex (a) waiving its confidentiality clause on the negotiations around NHS access to the drug Orkambi and (b) disclosing details of its offer to NHS England. more like this
star this property tabling member constituency Thornbury and Yate more like this
star this property tabling member printed
Luke Hall remove filter
star this property uin 164471 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-07-20more like thismore than 2018-07-20
star this property answer text <p>It is not in the Department’s gift to impose any requirement upon Vertex to waive its confidentiality clause or to disclose details of any offer in the negotiations around National Health Service access to the drug Orkambi. However, Ministers at the department have publicly urged Vertex to consider the offer made by NHS England and to waive confidentiality so that we can all see, in the interests of transparency, the kind of prices it is seeking to charge the NHS.</p> more like this
star this property answering member constituency Winchester more like this
unstar this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-07-20T09:43:39.613Zmore like thismore than 2018-07-20T09:43:39.613Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4450
unstar this property label Biography information for Luke Hall more like this
969030
star this property registered interest false more like this
star this property date less than 2018-09-06more like thismore than 2018-09-06
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
unstar this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi more like this
star this property house id 1 more like this
star this property legislature
25259
unstar this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what recent steps the Government has taken to ensure that (a) negotiations between Vertex Pharmaceuticals and NHS England on access to Orkambi for people with cystic fibrosis proceed without further delay and (b) an agreement is reached between the two parties. more like this
star this property tabling member constituency Thornbury and Yate more like this
star this property tabling member printed
Luke Hall remove filter
star this property uin 171383 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-09-14more like thismore than 2018-09-14
star this property answer text <p>It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the National Health Service. While Ministers are keeping a very close eye on negotiations, it is the responsibility of NHS England as the commissioner and the National Institute for Health and Care Excellence (NICE) as the independent body that is responsible for making recommendations on whether drugs and other treatments represent a clinically and cost-effective use of NHS resources, to work with Vertex to agree a deal to secure the best outcome for patients and a price for Orkambi that is fair and responsible.</p><p> </p><p>NHS England has proposed its best offer ever for a drug. This offer, in the region of £500 million over five years, is the largest ever commitment of its kind in the 70-year history of the NHS. This would guarantee immediate and expanded access to both Orkambi and the drug Kalydeco for patients who need it. Whilst it is disappointing that Vertex has not taken up NHS England’s offer, we are pleased to hear that it has responded positively to NHS England’s and NICE’s latest offer to meet. The Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy), the Secretary of State for Health (Rt. hon. Matt Hancock MP) and I have and continue to urge Vertex to reconsider this fair offer.</p>
star this property answering member constituency Winchester more like this
unstar this property answering member printed Steve Brine more like this
star this property grouped question UIN 171384 more like this
star this property question first answered
less than 2018-09-14T13:32:27.67Zmore like thismore than 2018-09-14T13:32:27.67Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4450
unstar this property label Biography information for Luke Hall more like this
969031
star this property registered interest false more like this
star this property date less than 2018-09-06more like thismore than 2018-09-06
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
unstar this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi more like this
star this property house id 1 more like this
star this property legislature
25259
unstar this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the oral contribution of the Parliamentary Under-Secretary of State for Health and Social Care of 17 July 2018, Official Report, column 384, what progress the Government has made on access to Orkambi in England since Vertex Pharmaceuticals was called on to accept NHS England’s proposal to make that drug available to people with cystic fibrosis. more like this
star this property tabling member constituency Thornbury and Yate more like this
star this property tabling member printed
Luke Hall remove filter
star this property uin 171384 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-09-14more like thismore than 2018-09-14
star this property answer text <p>It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the National Health Service. While Ministers are keeping a very close eye on negotiations, it is the responsibility of NHS England as the commissioner and the National Institute for Health and Care Excellence (NICE) as the independent body that is responsible for making recommendations on whether drugs and other treatments represent a clinically and cost-effective use of NHS resources, to work with Vertex to agree a deal to secure the best outcome for patients and a price for Orkambi that is fair and responsible.</p><p> </p><p>NHS England has proposed its best offer ever for a drug. This offer, in the region of £500 million over five years, is the largest ever commitment of its kind in the 70-year history of the NHS. This would guarantee immediate and expanded access to both Orkambi and the drug Kalydeco for patients who need it. Whilst it is disappointing that Vertex has not taken up NHS England’s offer, we are pleased to hear that it has responded positively to NHS England’s and NICE’s latest offer to meet. The Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy), the Secretary of State for Health (Rt. hon. Matt Hancock MP) and I have and continue to urge Vertex to reconsider this fair offer.</p>
star this property answering member constituency Winchester more like this
unstar this property answering member printed Steve Brine more like this
star this property grouped question UIN 171383 more like this
star this property question first answered
less than 2018-09-14T13:32:27.717Zmore like thismore than 2018-09-14T13:32:27.717Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4450
unstar this property label Biography information for Luke Hall more like this
1130724
star this property registered interest false more like this
star this property date less than 2019-06-07more like thismore than 2019-06-07
star this property answering body
Department for International Development more like this
star this property answering dept id 20 more like this
star this property answering dept short name International Development more like this
unstar this property answering dept sort name International Development more like this
star this property hansard heading Overseas Aid: Christianity more like this
star this property house id 1 more like this
star this property legislature
25259
unstar this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for International Development, what steps his Department is taking to ensure that UK aid reaches persecuted Christians. more like this
star this property tabling member constituency Thornbury and Yate more like this
star this property tabling member printed
Luke Hall remove filter
star this property uin 261524 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-06-14more like thismore than 2019-06-14
star this property answer text <p>The UK Aid Strategy commits the UK to be the lead on the “Leave No One Behind” promise. Our analysis of poverty and vulnerability looks at a range of factors that lead to exclusion including religious identity. Humanitarian assistance is provided on need, irrespective of race, religion or ethnicity and we work to ensure that aid reaches the most vulnerable including those from religious minorities.</p><p> </p><p>We work closely with the Foreign and Commonwealth Office who lead on the protection of freedom of religion and religious minorities.</p> more like this
star this property answering member constituency West Worcestershire more like this
unstar this property answering member printed Harriett Baldwin more like this
star this property question first answered
less than 2019-06-14T13:40:13.8Zmore like thismore than 2019-06-14T13:40:13.8Z
star this property answering member
4107
star this property label Biography information for Harriett Baldwin more like this
star this property tabling member
4450
unstar this property label Biography information for Luke Hall more like this
1130725
star this property registered interest false more like this
star this property date less than 2019-06-07more like thismore than 2019-06-07
star this property answering body
Department for International Development more like this
star this property answering dept id 20 more like this
star this property answering dept short name International Development more like this
unstar this property answering dept sort name International Development more like this
star this property hansard heading Non-governmental Organisations: Religion more like this
star this property house id 1 more like this
star this property legislature
25259
unstar this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for International Development, what assessment he has made of the potential merits of requiring international NGOs to consider religious vulnerability in their definition of need. more like this
star this property tabling member constituency Thornbury and Yate more like this
star this property tabling member printed
Luke Hall remove filter
star this property uin 261525 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-06-14more like thismore than 2019-06-14
star this property answer text <p>All DFID partners carry out comprehensive vulnerability assessments to ensure aid is reaching those most in need, including those from religious minorities as it is already recognised that religion may be a factor in causing vulnerability. We continue to discuss the treatment of minorities with the UN, our humanitarian partners and minority representatives.</p> more like this
star this property answering member constituency West Worcestershire more like this
unstar this property answering member printed Harriett Baldwin more like this
star this property question first answered
less than 2019-06-14T13:41:33.177Zmore like thismore than 2019-06-14T13:41:33.177Z
star this property answering member
4107
star this property label Biography information for Harriett Baldwin more like this
star this property tabling member
4450
unstar this property label Biography information for Luke Hall more like this